Appointed
Gemma Brown
principal accounting officer
BRNS ·
Barinthus Biotherapeutics plc.
and Ms. Brown as principal accounting officer
Ready 8-Ks
50
Latest filing
August 25, 2026, 6:01 AM ET
Top materiality
0.90
Event mix
earnings ×18 · other_material ×15 · leadership ×8
Sentiment
12 pos · 9 neg · 29 neu
Latest earnings
reported 2026-Q2
Executive change
recent →
Recent 8-K filings for BRNS
Highest-materiality recent filing
Barinthus (BRNS) merges with Clywedog; Clywedog stockholders to own ~66% of combined company
- Clywedog stockholders will receive ~4.36 Topco shares per Clywedog share; Barinthus shareholders receive 1 Topco share per share.
- Clywedog stockholders to own ~66% of combined entity; Barinthus shareholders ~34%.
-
Barinthus Bio sets scheme exchange ratio at 0.111; merger with Clywedog to close Sept 3
Scheme exchange ratio set at 0.111, ensuring Topco stock price meets Nasdaq minimum listing requirement.
-
Barinthus Bio Q2 net loss $10.6M; VTP-1000 trial enrollment complete; merger with Clywedog on track
Net loss of $10.6M ($0.26 per share) vs $5.5M in Q1 2026; cash $59.6M as of June 30.
-
Barinthus Biotherapeutics gets Nasdaq extension to Dec 28, 2026; listing moved to Capital Market
Received 180-day extension from Nasdaq until Dec 28, 2026 to regain $1.00 minimum bid price for ADSs.
-
Barinthus Bio Q1 net loss narrows to $5.5M; merger with Clywedog on track
Net loss of $5.5M ($0.14/shr) vs $19.6M ($0.49/shr) in Q1 2025.
-
Barinthus Bio reports FY2025 net loss $66.5M; merger with Clywedog on track for Q2 2026
Proposed all-stock merger with Clywedog expected to close Q2 2026; combined entity to trade as CLYD.
-
Barinthus Biotherapeutics receives Nasdaq delinquency notice over bid price below $1.00 per ADR
On Dec 30, 2025, Nasdaq notified Barinthus that its ADS bid price was below $1.00 for 30 consecutive business days, violating Listing Rule 5450(a)(1).
-
Barinthus Bio Phase 1 AVALON trial of VTP-1000 shows safety, dose-dependent effect in celiac disease
VTP-1000 well-tolerated in SAD portion; no treatment-related serious adverse events.
-
Barinthus Bio Q3 net loss $14.6M; all-stock merger with Clywedog
Net loss of $14.6M ($0.36/share) in Q3 2025 vs $21.1M loss in Q2 2025.
-
Barinthus (BRNS) merges with Clywedog; Clywedog stockholders to own ~66% of combined company
Clywedog stockholders will receive ~4.36 Topco shares per Clywedog share; Barinthus shareholders receive 1 Topco share per share.
-
Barinthus Bio amends 8-K to correct VTP-850 trial statement; reports Q2 net loss of $21.1M
Net loss $21.1M ($0.52/share) vs $19.7M ($0.49/share) in Q1 2025.
-
Barinthus Bio Q2 net loss $21.1M ($0.52/share); cash $87.8M, runway into 2027
Cash, cash equivalents & restricted cash $87.8M at June 30, 2025, down $12.8M from Q1.
-
Net loss $19.6M ($0.49/share) vs $15.5M ($0.40) in Q1 2024; R&D spending down to $8.3M from $11.1M.
-
Barinthus Bio FY2024 net loss $61.1M; cash runway into 2027; VTP-1000 data Q3 2025
Net loss of $61.1M ($1.55 per share) vs $73.3M in 2023; goodwill impairment of $12.2M.
-
Barinthus Bio restructures: cuts 65% workforce, shifts focus to celiac VTP-1000
Workforce reduction of ~65%; plans to close UK site, consolidate operations in Germantown, MD.
-
Barinthus/Arbutus HBV data: 23% HBsAg loss with nivolumab; 2 functional cures in Phase 2b
IM-PROVE II Group C: 23% (3/13) on imdusiran + VTP-300 + low-dose nivolumab achieved HBsAg loss by Week 48.
-
Net loss of $8.1M ($0.21/sh) vs $16.9M ($0.43/sh) in Q2; revenue of $15.0M from AstraZeneca Vaxzevria royalty share.
-
Barinthus Bio Q2 2024 net loss $16.9M; prioritizes HBV and celiac programs; CMO hired
Net loss of $16.9M ($0.43 per share) compared to $15.5M ($0.40) in Q1 2024.
-
Pipeline focused on VTP-300 for chronic hepatitis B and VTP-1000 for celiac disease; ongoing Phase 1 trial of VTP-850 in prostate cancer to be completed.
-
Barinthus Bio VTP-300 data: 76% eligible to stop NUC therapy; significant HBsAg reduction vs placebo
HBV003 (Phase 2b): 76% (16/21) eligible for NUC discontinuation; 19% achieved undetectable HBsAg.
-
Barinthus Bio Q1 net loss $15.5M; VTP-200 misses stat sig; VTP-1000 IND cleared; CMO appointed
Net loss was $15.5M ($0.40/share), compared to $18.2M ($0.48) in Q1 2023; revenue nil.
-
Barinthus Bio Q1 net loss $15.5M ($0.40/sh); cash $130M; VTP-1000 IND cleared for celiac trial
Net loss attributable to shareholders of $15.5M vs $18.2M in Q1 2023; revenue nil (vs $0.5M).
-
APOLLO trial met primary safety endpoint; VTP-200 well-tolerated with no treatment-related Grade 3+ AEs or SAEs.
-
Barinthus Bio FY2023 net loss $73.3M, revenue drops to $0.8M, cash down to $142.1M
Net loss of $73.3M ($1.91 per share) vs net income of $5.3M in 2022; revenue fell to $0.8M from $44.7M on lower Vaxzevria royalties.
-
Barinthus secures up to $34.8M CEPI funding for MERS vaccine VTP-500 development
CEPI to provide $34.8M to advance VTP-500 through Phase II trials and develop 100,000-dose ready reserve.
-
In HBV003, 31% of participants with screening HBsAg ≤200 IU/mL had >1 log HBsAg reductions.
-
Barinthus Biotherapeutics (fka Vaccitech) begins trading under BRNS, presents Phase 2 HBV data
Company renamed to Barinthus Biotherapeutics; Nasdaq ticker changes from VACC to BRNS effective Nov 7, 2023.
-
Vaccitech Q2 net loss $23.8M ($0.62 per share); cash $173M extends runway into Q2 2025
Net loss $23.8M, widened from $18.2M in Q1 2023; revenue $0.3M from AstraZeneca royalties.
-
Dr. Margaret Marshall retired as Chief Medical Officer of Vaccitech effective July 20, 2023.
-
Vaccitech reports positive final Phase 1b/2 HBV002 data; two patients achieve non-detectable HBsAg
Two of five patients with baseline HBsAg <100 IU/mL in Group 3 developed non-detectable HBsAg, sustained eight months after last dose.
-
Vaccitech Q1 net loss $18.2M vs $2.6M income; cash $191.3M; positive HBV, HPV data
Net loss per share $0.48 vs prior year income $0.07; revenue fell to $0.5M from $15.0M due to lower Vaxzevria royalties.
-
Vaccitech reports net income of $5.3M for FY2022 vs $50.9M loss in 2021; revenue jumps to $44.7M
Net income attributable to shareholders of $5.3M ($0.14 diluted EPS) vs net loss of $50.9M ($1.94 loss) in 2021.
-
Vaccitech reports Q2 net income of $15.7M on $17.1M in Vaxzevria royalties
Net income $15.7M ($0.41 diluted EPS) vs $2.6M ($0.068) in Q1 2022.
-
VTP-300 shows durable HBsAg reductions in chronic hepatitis B; no serious adverse events
Updated interim data (n=39) shows VTP-300 as monotherapy or +nivolumab had no treatment-related SAEs; 2 mild transaminitis cases.
Executive changes
Appointed
William Enright
principal financial officer
BRNS ·
Barinthus Biotherapeutics plc.
appointed William Enright, the Company’s Chief Executive Officer, as principal financial officer
Departed
Gemma Brown
Chief Financial Officer
BRNS ·
Barinthus Biotherapeutics plc.
Effective as of April 30, 2025, the Company terminated the employment of Gemma Brown as Chief Financial Officer in connection with its restructuring plan that was announced in 2025.
Departed
Gemma Brown
Chief Financial Officer
BRNS ·
Barinthus Biotherapeutics plc.
the employment of Gemma Brown effective as of April 30, 2025
Departed
Graham Griffiths
Chief Operating Officer
BRNS ·
Barinthus Biotherapeutics plc.
the Company will terminate the employment of Graham Griffiths effective as of June 30, 2025
Departed
Nadège Pelletier
Chief Scientific Officer
BRNS ·
Barinthus Biotherapeutics plc.
On November 25, 2024, Nadège Pelletier, Ph.D., notified Barinthus Biotherapeutics plc (the "Company") that she will step down as Chief Scientific Officer of the Company effective February 2, 2025.
Role change
Graham Griffiths
Chief Operating Officer
BRNS ·
Barinthus Biotherapeutics plc.
Effective September 1, 2024 (the “Effective Date”), Barinthus Biotherapeutics plc (the “Company”) has promoted Graham Griffiths, the Company’s Chief Business Officer, to Chief Operating Officer.
Departed
Dr. Margaret Marshall
Chief Medical Officer
BRNS ·
Barinthus Biotherapeutics plc.
On July 20, 2023, Dr. Margaret Marshall notified Vaccitech plc (the “Company”) of her intention to retire from her position as Chief Medical Officer of the Company, effective immediately.
Departed
Chris Ellis
Chief Operating Officer
BRNS ·
Barinthus Biotherapeutics plc.
On April 24, 2023, Chris Ellis, our Chief Operating Officer (principal operating officer), informed Vaccitech plc (the “Company”) of his retirement from the Company, effective October 31, 2023.
Appointed
Gemma Brown
Chief Financial Officer
BRNS ·
Barinthus Biotherapeutics plc.
the Board of Directors (the “Board”) of the Company had appointed Gemma Brown as the Company’s Chief Financial Officer.
Appointed
Gemma Brown
Chief Financial Officer
BRNS ·
Barinthus Biotherapeutics plc.
Effective September 15, 2022, the Board of Directors (the “Board”) of Vaccitech plc (the “Company”) appointed Gemma Brown, age 32, as the Company’s Chief Financial Officer.
Departed
Georgy Egorov
Chief Financial Officer
BRNS ·
Barinthus Biotherapeutics plc.
On September 14, 2022, the Company terminated the employment of Georgy Egorov in its entirety, effective immediately.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.60 · Most common event earnings